Merck & Co. Inc. (MRK)

Q2 2025 began with market volatility due to tariff announcements, resulting in SPY losing 0.87% and VYM declining by 3.54%. Since inception, my watchlist has a CAGR of 14.61%, outperforming SPY and VY...

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

While the strategy involves buying the Dogs of the Dow at the start of January, there are a few still worth betting on as markets regain lost ground.

The performance of healthcare companies is relatively uncorrelated with broader macroeconomic growth.

One great thing about a crash or downturn in the markets is that it can allow you to go bargain hunting fairly easily. Many stocks have been falling this year, and if you're a dividend investor, you k...

When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting som...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of Excellence in Wilmington, Delaware.

U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall St...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.